IL162600A0 - Cc-chemokine mutants as cc-chemokine antagonists - Google Patents

Cc-chemokine mutants as cc-chemokine antagonists

Info

Publication number
IL162600A0
IL162600A0 IL16260002A IL16260002A IL162600A0 IL 162600 A0 IL162600 A0 IL 162600A0 IL 16260002 A IL16260002 A IL 16260002A IL 16260002 A IL16260002 A IL 16260002A IL 162600 A0 IL162600 A0 IL 162600A0
Authority
IL
Israel
Prior art keywords
chemokine
mutants
antagonists
chemokine antagonists
ccl5
Prior art date
Application number
IL16260002A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of IL162600A0 publication Critical patent/IL162600A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL16260002A 2001-12-17 2002-12-16 Cc-chemokine mutants as cc-chemokine antagonists IL162600A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01000761 2001-12-17
PCT/EP2002/014325 WO2003051921A1 (en) 2001-12-17 2002-12-16 Chemokine mutants acting as chemokine antagonists

Publications (1)

Publication Number Publication Date
IL162600A0 true IL162600A0 (en) 2005-11-20

Family

ID=8176112

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16260002A IL162600A0 (en) 2001-12-17 2002-12-16 Cc-chemokine mutants as cc-chemokine antagonists

Country Status (10)

Country Link
US (1) US7553483B2 (xx)
EP (1) EP1458756B1 (xx)
JP (1) JP2005525089A (xx)
AT (1) ATE421974T1 (xx)
AU (1) AU2002358144B2 (xx)
CA (1) CA2468790A1 (xx)
DE (1) DE60231057D1 (xx)
ES (1) ES2320743T3 (xx)
IL (1) IL162600A0 (xx)
WO (1) WO2003051921A1 (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1575608B1 (en) 2002-12-23 2008-05-07 Laboratoires Serono SA Use of cc-chemokine ccl5/rantes mutants against liver diseases
DE60304435T2 (de) * 2004-01-19 2006-08-24 Ares Trading S.A. Verfahren zur Reinigung von in Bakterien exprimierten Proteinen
US8445442B2 (en) 2007-04-26 2013-05-21 University Of Vermont And State Agricultural College CCL18 and CCL3 methods and compositions for detecting and treating cancer
MX2010001307A (es) 2007-08-02 2010-07-30 Novimmune Sa Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos.
WO2010071610A1 (en) * 2008-12-19 2010-06-24 Agency For Science, Technology And Research (A*Star) Severe chikungunya biomarkers
EP2380975A1 (de) * 2010-04-22 2011-10-26 Scil Proteins GmbH Verfahren zur Herstellung von rekombinantem Thrombin
US9717777B2 (en) 2010-05-05 2017-08-01 Rappaport Family Institute For Research In The Medical Sciences Use of CCL1 in therapy
WO2011138785A2 (en) 2010-05-05 2011-11-10 Rappaport Family Institute For Research In The Medical Sciences Use of ccl1 in therapy
US10967015B2 (en) * 2015-06-15 2021-04-06 New York University Method of treatment using oncolytic viruses
WO2017077062A1 (en) * 2015-11-05 2017-05-11 Ludwig-Maximilians-Universität München A peptide derived from human neutrophile peptide 1
KR102682118B1 (ko) * 2016-04-29 2024-07-08 주식회사유한양행 Ccl3 변이체를 포함하는 융합 단백질 및 이의 용도
EP4413026A1 (en) 2021-10-06 2024-08-14 Virothera Ltd Novel immune regulator

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07502404A (ja) * 1991-12-23 1995-03-16 ブリティッシュ　バイオ−テクノロジー　リミテッド 幹細胞阻害タンパク質
PL182786B1 (pl) * 1994-12-08 2002-02-28 Glaxo Group Ltd Polipeptyd, sekwencja kwasu nukleinowego, wektor, komórka gospodarza, środek farmaceutyczny, oraz sposób otrzymywania polipeptydu
JP2001506492A (ja) * 1996-12-05 2001-05-22 ヒューマン ゲノム サイエンシズ インク． ヒトケモカインβ−１３
EP0949271A1 (en) 1996-12-05 1999-10-13 Kyowa Hakko Kogyo Co., Ltd. Novel dna, novel protein, and novel antibody
EP0906954A1 (en) 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
DE69832216T2 (de) 1997-12-23 2006-05-24 Fondazione Centro San Raffaele Del Monte Tabor RANTES-Mutanten und therapeutische Anwendungen davon
JPH11243960A (ja) 1998-03-06 1999-09-14 Shionogi & Co Ltd ヒトｃｃ型ケモカインエオタキシン３
CA2335105C (en) * 1998-07-22 2010-05-11 Osprey Pharmaceuticals Limited Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
WO2000078334A1 (en) * 1999-06-17 2000-12-28 University Of Maryland Biotechnology Institute Chimeric chemokine-antigen polypeptides and uses therefor
CA2405557C (en) 2000-04-12 2013-09-24 Human Genome Sciences, Inc. Albumin fusion proteins
UA77950C2 (en) 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis

Also Published As

Publication number Publication date
DE60231057D1 (de) 2009-03-19
CA2468790A1 (en) 2003-06-26
US20050220757A1 (en) 2005-10-06
JP2005525089A (ja) 2005-08-25
AU2002358144B2 (en) 2008-10-02
AU2002358144A1 (en) 2003-06-30
ATE421974T1 (de) 2009-02-15
EP1458756A1 (en) 2004-09-22
EP1458756B1 (en) 2009-01-28
ES2320743T3 (es) 2009-05-28
WO2003051921A1 (en) 2003-06-26
US7553483B2 (en) 2009-06-30

Similar Documents

Publication Publication Date Title
HK1095357A1 (en) Factor vii or viia gla domain variants
IL214607A0 (en) 2,4-pyrimidinedinediamine compounds and their use in the manufacture of medicaments for the treatment of autoimmune disases
AU2001254624A1 (en) Human coagulation factor vii variants
IL162600A0 (en) Cc-chemokine mutants as cc-chemokine antagonists
GB0111186D0 (en) Novel compounds
NZ515964A (en) A method for the prophylaxis and/or treatment of medical disorders
UA86345C2 (ru) Применение остеопротегерина для лечения и/или предотвращения фиброза
GB0202556D0 (en) Novel Protein
HK1154623A1 (en) Isolated luciferases and the use thereof
WO2003057856A3 (en) Dominant negative proteins and methods thereof
YU102503A (sh) Kondenzovani pirimidinski dhfr inhibitori kao antibakterijska sredstva
WO2003048205A3 (fr) Proteines a activite inhibitrice de l'il-6
NZ531516A (en) Aminopeptidase
TW200510451A (en) Novel antimicrobial peptide isolated from penaeus monodon
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
GB2374871A (en) Peptide fragments of colostrinin and their use
ZA961419B (en) Human DNase I variants.
WO2002086067A3 (en) Mycobacterial sulfation pathway proteins and methods of use thereof
NZ591879A (en) Detection of mutations in a gene associated with resistance to viral infection, OAS1
WO2003025004A3 (en) Purified bacterial polypeptides involved in nucleic acid processing
WO2004058954A3 (en) Crystal structure of aspartate semialdehyde dehydrogenases from pseudomonas aeruginosa and uses thereof
WO2004011638A3 (en) Deoxyuridine 5' triphosphate nucleotidohydrolase polypeptides and structures
WO2003087141A3 (en) Adenine phosphoryltransferase from escherichia coli
IL163651A0 (en) Nucleotide sequence coding for a tolc and a defined amino acid sequence
WO2004042044A3 (en) Crystal structures of bacterial guanylate kinases